Apellis Pharmaceuticals's total assets for Q1 2026 were $1.08B, an increase of 0.68% from the previous quarter. APLS total liabilities were $667.61M for the fiscal quarter, a -5.32% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.